Free Trial
NASDAQ:SGMT

Sagimet Biosciences Q2 2025 Earnings Report

Sagimet Biosciences logo
$7.72 +0.65 (+9.12%)
As of 03:34 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Sagimet Biosciences EPS Results

Actual EPS
-$0.32
Consensus EPS
-$0.52
Beat/Miss
Beat by +$0.20
One Year Ago EPS
N/A

Sagimet Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Sagimet Biosciences Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Wednesday, August 13, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Sagimet Biosciences' Q3 2025 earnings is scheduled for Thursday, November 13, 2025, with a conference call scheduled at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Sagimet Biosciences Earnings Headlines

Musk’s Project Colossus could mint millionaires
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.tc pixel
Q2 Earnings Estimate for SGMT Issued By Wedbush
See More Sagimet Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sagimet Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sagimet Biosciences and other key companies, straight to your email.

About Sagimet Biosciences

Sagimet Biosciences (NASDAQ:SGMT), a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

View Sagimet Biosciences Profile

More Earnings Resources from MarketBeat